In a phase 2 trial in participants with obesity and MASLD, once-weekly treatment with the GIP/GLP-1/GCG triple agonist retatrutide resulted in substantial reductions in liver fat, body weight, abdominal visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (ASAT), serum lipids
Or why isn't it on the other side dropping my basal metabolic rate so now I'm still gaining weight, or I'm staying at a sort of consistent level even at this lower calorie intake that the GLP-1 is allowing for me to have
You can then benefit from personalized treatment programs we offer, including nutrition, supplements, Hydrogen Inhalation, and IV Therapy to help improve your health
Long-term exposure is associated with an increased risk of liver cancer, immune system suppression, and growth impairment in children
But fortunately, scientists have come up with a solution for this TRT side effect